newer
fluoroquinolon
levofloxacin
moxifloxacin
gatifloxacin
abstract
gemifloxacin
sever
attribut
make
excel
choic
therapi
lower
respiratori
tract
infect
particular
excel
intrins
activ
streptococcu
pneumonia
haemophilu
influenza
moraxella
catarrhali
atyp
respiratori
pathogen
fluoroquinolon
may
use
monotherapi
treat
highrisk
patient
acut
exacerb
chronic
bronchiti
patient
communityacquir
pneumonia
requir
hospitalis
admiss
intens
care
overal
newer
fluoroquinolon
often
achiev
clinic
cure
rate
patient
howev
rate
may
lower
hospitalacquir
pneumonia
infect
treat
basi
anticip
organ
evalu
risk
factor
specif
pathogen
pseudomona
aeruginosa
set
antipseudomon
fluoroquinolon
may
use
combin
antipseudomon
concern
rais
widespread
use
possibl
misus
fluoroquinolon
emerg
resist
among
pneumonia
enterobacteriacea
p
aeruginosa
number
pharmacokinet
paramet
peak
concentr
antibacteri
dose
cmax
area
concentrationtim
curv
relationship
pharmacodynam
paramet
minimum
inhibitori
mutant
prevent
concentr
mic
mpc
respect
propos
predict
effect
fluoroquinolon
bacteri
kill
emerg
resist
higher
cmaxmic
cmaxmpc
ratio
either
result
dose
administr
suscept
organ
may
lead
better
clinic
outcom
decreas
emerg
resist
respect
pharmacokinet
profil
optimis
target
lowlevel
resist
minor
subpopul
bacteria
often
exist
infect
may
help
preserv
fluoroquinolon
class
end
optimis
mpc
cmaxmpc
ratio
import
particularli
pneumonia
set
lower
respiratori
tract
infect
agent
moxifloxacin
gemifloxacin
high
ratio
organ
prefer
agent
ciprofloxacin
low
ratio
avoid
agent
levofloxacin
gatifloxacin
intermedi
ratio
pneumonia
may
worthwhil
consid
altern
dose
administr
strategi
use
higher
dosag
erad
lowlevel
resist
variant
must
cours
balanc
potenti
toxic
innov
approach
use
fluoroquinolon
worth
test
vitro
experi
well
clinic
trial
lower
respiratori
tract
infect
includ
acut
often
occur
togeth
frequent
bronchiti
acut
exacerb
chronic
bronchiti
result
aetiolog
factor
exposur
aecb
communityacquir
pneumonia
cap
cigarett
smoke
two
diseas
entiti
reand
hospitalacquir
pneumonia
hap
present
spectrum
chronic
obstruct
pulmonari
diseas
copd
afflict
million
indiacut
bronchiti
inflammatori
condit
vidual
us
alon
aecb
patient
tracheobronchi
tree
cough
characteris
increas
cough
sputum
prowithout
sputum
product
predomin
featur
duction
worsen
dyspnoea
result
respirin
absenc
physic
radiograph
find
atori
decompens
without
object
docuof
pneumonia
one
commonli
ment
caus
pneumonia
role
encount
diseas
entiti
clinic
practic
bacteri
infect
underli
aetiolog
acut
bronchiti
may
due
underli
infecaecb
debat
increas
protiou
noninfecti
trigger
microbiolog
duction
purul
sputum
presenc
neutrostudi
acut
bronchiti
identifi
aetiolog
phil
bacteria
sputum
appear
pathogen
case
acut
antibodi
respons
respiratori
pathobacteria
respons
episod
gen
suggest
bacteria
play
central
role
virus
thought
underli
aetiprocess
also
note
sever
placeboconolog
remaind
import
virus
includ
troll
trial
document
better
outcom
influenza
virus
parainfluenza
virus
respirapati
aecb
treat
antibacteri
tori
syncyti
viru
common
cold
virus
one
remark
studi
perform
tunisia
coma
corona
virus
rhinovirus
bacpar
use
ofloxacin
placebo
patient
terial
caus
acut
bronchiti
less
common
exacerb
copd
requir
mechan
import
aetiolog
includ
bordatella
pertussi
ventil
combin
frequenc
death
mycoplasma
pneumonia
chlamydophila
hospit
need
addit
antibacteri
chlamydia
pneumonia
streptococcu
pneumoniwa
significantli
lower
patient
given
ofloxa
haemophilu
influenza
seem
acin
absolut
risk
reduct
ci
caus
agent
acut
bronchiti
although
p
durat
mechan
may
play
role
secondari
infect
sinc
ventil
hospit
stay
shorter
treata
part
resid
respiratori
flora
ed
group
absolut
differ
day
ci
diagnosi
acut
bronchiti
depend
mainli
day
ci
respect
physic
examin
radiographi
exclud
sign
pneumonia
routin
sputum
gramstain
recent
review
sever
longitudin
studi
cultur
low
yield
detect
b
pertussi
group
patient
copd
conclud
pneumonia
c
pneumonia
aecb
episod
infecti
origin
chronic
bronchiti
defin
presenc
caus
bacteria
h
influenza
product
cough
month
succesmoraxella
catarrhali
pneumonia
h
parains
year
patient
caus
fluenza
pseudomona
aeruginosa
pacough
infect
mycobacterium
tuberti
signific
structur
lung
impair
culosi
carcinoma
lung
bronchiectasi
cystic
manifest
forc
expiratori
volum
secfibrosi
chronic
congest
heart
failur
ond
like
infect
exclud
chronic
bronchiti
emphysewith
h
influenza
p
aeruginosa
approxim
infect
caus
virus
tere
particular
set
see
section
influenza
respiratori
syncyti
vipneumocysti
jiroveci
formal
carinii
endemrus
caus
atyp
bacteria
ic
fungi
cryptocococcu
neoformam
histoplasma
legionella
spp
pneumonia
c
capsulatum
blastomyc
dermatid
coccidioid
pneumonia
immiti
constitut
aetiolog
agent
often
depend
epidemiolog
host
facpneumonia
rank
first
caus
death
tor
frequenc
pathogen
vari
infect
sixth
lead
caus
death
set
infect
acquir
gener
us
million
case
cap
variabl
includ
season
year
geographioccur
year
us
result
approximatec
locat
environment
exposur
host
facli
million
physician
visit
tor
age
smoke
alcohol
use
underlyhospitalis
death
infec
ill
tiou
diseas
societi
america
idsa
practic
guidelin
defin
cap
acut
infect
hap
defin
inflammatori
condit
pulmonari
parenchyma
associ
lung
parenchyma
occur
hour
hosleast
symptom
acut
infect
accompapit
admiss
caus
infecti
agent
nie
presenc
acut
infiltr
chest
present
incub
time
admiss
radiograph
auscultatori
find
consist
hap
second
common
nosocomi
infecpneumonia
alter
breath
sound
localt
lead
caus
hospit
morbid
ise
rale
patient
hospitalis
resid
mortal
hap
mainli
bacteri
aetioloa
longtermcar
facil
day
onset
gy
gramneg
pathogen
gramposit
pathoof
symptom
symptom
acut
lower
respiragen
polymicrobi
infect
respons
tori
infect
often
includ
two
case
follow
fever
hypothermia
rigor
sweat
new
respect
caus
gramneg
bacteria
incough
without
sputum
product
chang
clude
p
aeruginosa
enterobact
spp
colour
respiratori
secret
patient
acinetobact
spp
caus
gramposit
chronic
cough
chest
discomfort
onset
bacteria
includ
staphylococcu
aureu
dyspnoea
mani
patient
also
nonspecif
pneumonia
hap
develop
third
symptom
fatigu
myalgia
abdomin
fourth
day
hospitalis
ie
earlyonset
hap
pain
anorexia
headach
usual
caus
pathogen
cap
cap
may
viral
bacteri
fungal
aetioloa
number
antimicrobi
agent
use
gy
howev
caus
pathogen
may
idenfor
treatment
lower
respiratori
tract
infectifi
patient
despit
extens
tion
perhap
newest
efficaci
laboratori
test
aetiolog
virus
includ
antibacteri
fluoroquinolon
lesher
et
influenza
virus
respiratori
syncyti
viru
al
introduc
prototyp
quinolon
nalidix
adenoviru
parainfluenza
viru
herp
simplex
viacid
nalidix
acid
becam
commonli
ru
hantaviru
sar
coronaviru
use
antibacteri
treatment
uncomplicatmost
commonli
encount
bacteria
includ
ed
urinari
tract
infect
reliabl
covpneumonia
h
influenza
ere
enterobacteriacea
howev
nalidix
accatarrhali
atyp
bacteria
id
use
system
infect
limit
pneumonia
c
pneumonia
low
serum
tissu
concentr
narrow
legionella
speci
coantibacteri
spectrum
emerg
bacteriinfect
atyp
bacteri
pathogen
estial
resist
numer
quinolon
deriv
mate
occur
patient
nalidix
acid
develop
studi
cap
enter
gramneg
bacteria
subsequ
two
decad
fluoroquinolon
common
caus
cap
yet
may
encounwith
improv
pharmacokinet
pharmacodi
namic
properti
introduc
approv
agent
possess
excel
activ
clinic
use
placement
fluorin
atom
pneumonia
atyp
respiratori
pathogen
posit
quinolon
nucleu
figur
legionella
pneumophilia
pneumonia
replac
sidechain
nalidix
c
pneumonia
howev
concern
acid
piperazin
group
markedli
enhanc
rais
widespread
use
possimicrobiolog
activ
fluoroqu
misus
increas
report
fluoronolon
ciprofloxacin
extend
quinolon
resist
among
pneumonia
entergramneg
spectrum
still
lack
reliabl
coverag
import
gramposit
respiratori
obacteriacea
p
aeruginosa
pathogen
pneumonia
limit
recent
sever
excel
review
use
role
clinic
set
aecb
nosocomi
fluoroquinolon
respiratori
tract
infect
pneumonia
cystic
fibrosi
gramnegaappear
follow
updat
data
tive
bacilli
predomin
pathogen
rethi
rapidli
evolv
field
emphasi
centli
fluoroquinolon
levofloxacin
moxifloxacin
gatifloxacin
introduc
use
fluoroquinolon
clinic
practic
excel
gramneg
activ
includ
accord
structur
p
aeruginosa
microbiolog
spectrum
modest
activ
methicillinresist
aureu
mrsa
weak
activ
follow
classif
system
base
pneumonia
signific
anaerob
acth
integr
microbiolog
susceptibilit
tie
pharmacokinet
data
earli
agent
group
includ
norfloxacin
lomefloxacin
moder
activ
gramneg
bacteria
enoxacin
ofloxacin
ciprofloxacin
addit
pharmacokinet
releg
fluorin
atom
posit
quinolon
treatment
urinari
tract
infect
sexuallynucleu
replac
sidechain
transmit
diseas
chemic
modif
nalidix
acid
piperazin
group
figur
quinolon
nucleu
led
agent
enhanc
acmarkedli
enhanc
microbiolog
activ
tiviti
gramneg
improv
pharag
allow
coverag
wide
rang
grammacokinet
follow
alter
neg
bacteria
includ
p
aeruginosa
led
improv
activ
earli
member
group
norfloxacin
pneumonia
anaerob
retain
lomefloxacin
enoxacin
avail
oralimprov
pharmacokinet
properti
ly
releg
treatment
urinari
tract
infect
achiev
lack
signific
activ
p
aeruginosa
widespread
use
urinari
tract
well
gramposit
bacteria
anaerob
system
infect
also
concentr
group
includ
origin
quinolon
pulmonari
alveolar
macrophag
give
nalidix
acid
cinoxin
share
either
enhanc
activ
intracellular
pathogen
bicycl
quinolon
nucleu
naphthyridon
chlamydia
mycoplasma
legionella
deriv
nucleu
nitrogen
atom
spp
despit
advanc
secondgener
posit
figur
agent
avail
agent
lack
adequ
activ
import
oral
use
use
limit
uncomgramposit
bacteria
mrsa
plicat
urinari
tract
infect
pneumonia
clinic
use
activ
achiev
adequ
serum
tissu
concentr
anaerob
bacteria
lack
signific
activ
p
aeruginosa
gramposit
bacteria
anaerob
thirdgener
quinolon
secondgener
quinolon
key
featur
thirdgener
quinolon
key
featur
secondgener
quiar
nolon
improv
pharmacokinet
allow
daili
late
member
achiev
adequ
serum
tissu
dose
administr
concentr
use
treat
system
infect
enhanc
activ
pneumonia
group
includ
levofloxacin
sparfloxacin
addit
coverag
aerob
gramposit
grepafloxacin
gatifloxacin
gemifloxacin
gramneg
organ
although
moxifloxacin
levofloxacin
lisom
ofloxacin
activ
vitro
anaerob
efficaci
agent
group
structur
chang
treat
anaerob
infect
estabsuch
modif
piperazin
group
lish
use
infect
approv
quinolon
nucleu
addit
methyl
us
fda
us
fda
advis
group
alkyl
ring
structur
reserv
trovafloxacin
therapi
lifethreaten
posit
addit
methoxi
group
infect
requir
inpati
treatment
posit
figur
structur
chang
imth
risk
hepatotox
clinafloxacin
prove
pharmacokinet
compound
withdrawn
market
signific
allow
singl
daili
dose
administr
enphototox
hanc
activ
pneumonia
garenoxin
novel
desfluoro
quinolon
drug
also
enhanc
antimicrobi
activwith
broad
antimicrobi
spectrum
coverag
iti
legionella
chlamydia
mycoplasma
similar
trovafloxacin
remov
fluorin
spp
basi
minimum
inhibitori
conatom
differenti
drug
centrat
mic
thirdgener
quinolon
fluoroquinolon
may
decreas
toxic
levofloxacin
may
less
activ
secondha
yet
releas
market
despit
gener
quinolon
ciprofloxacin
initi
report
favour
safeti
profil
hypop
aeruginosa
howev
report
clinic
failtens
encount
garenoxacin
ure
levofloxacin
p
aeruginosa
infect
compar
drug
phase
iii
clinic
rare
may
vitro
disadvantri
clinic
signific
advers
effect
tage
levofloxacin
may
compens
yet
determin
reevalu
pharmacokinet
profil
patient
result
antibacteri
research
develop
prioriti
superior
blood
tissu
concentr
develop
compani
bristolmy
squibb
regrepafloxacin
remov
market
centli
announc
product
reacquir
signific
potenti
lifethreatenbi
initi
licens
compani
toyama
chemi
tachyarrythmia
caus
correct
qt
qtc
cal
interv
prolong
sparfloxacin
remov
market
unaccept
mechan
action
resist
phototox
gemifloxacin
recent
quinolon
kill
bacteria
bind
inmemb
group
enhanc
activ
hibit
activ
bacteri
topoisomeras
partic
pneumonia
variabl
activ
anaerularli
topoisomeras
ii
dna
gyras
toob
recent
gain
us
fda
approv
poisomeras
iv
enzym
essenti
use
cap
aecb
bacteri
dna
synthesi
mainten
dna
gyras
encod
gyra
gyrb
gene
duce
neg
supercoil
dna
wherea
toth
key
featur
fourthgener
quinolon
poisomeras
iv
encod
parc
pare
enhanc
activ
anaerob
gene
design
grla
grlb
aureu
involv
dna
decaten
dna
gyras
group
includ
trovafloxacin
clinafloxacin
primari
target
quinolon
moxifloxacin
garenoxacin
structur
gramneg
bacteria
topoisomeras
iv
modif
halogen
substitut
primari
target
gramposit
bacteria
alposit
quinolon
clinafloxacin
use
though
except
occur
naphthyridon
nucleu
place
quinolon
nucleu
result
enhanc
antimicrobi
activ
resist
quinolon
aris
spontaneagainst
anaerob
bacteroid
fragili
ou
mutat
occur
parc
grlab
gyra
b
gene
due
acquisit
resisacin
gemifloxacin
trovafloxacin
levofloxacin
tanc
gene
case
macrolid
ermam
moxifloxacin
gatifloxacin
garenoxmef
gene
methicillin
sccmec
resist
acin
also
select
resist
variant
thu
fluoroquinolon
resist
aris
de
novo
methicillinsensit
resist
aureu
mani
differ
geograph
foci
rather
frequent
levofloxacin
trovafloxacin
gatifrom
spread
singl
clone
appear
floxacin
garenoxacin
overal
resist
canada
instanc
methoxi
quinolon
gatifloxacin
moxifloxacin
thought
due
select
pressur
fluoroand
desfluoro
quinolon
garenoxacin
apquinolon
use
upon
multipl
indigen
unrel
pear
select
resist
mutant
pneumonia
strain
throughout
countri
horizont
aureu
lower
rate
older
quispread
resist
clone
may
still
occur
although
nolon
clear
differthi
appear
uncommon
date
enc
exist
may
function
intrins
activ
compound
gramposit
organ
singlestep
mutabacteria
instanc
one
studi
show
tion
parc
grlab
gene
caus
lowlevel
activ
compound
pneumonia
resist
ciprofloxacin
mutat
gemifloxacin
mic
follow
gyrab
gene
alon
usual
associ
clinafloxacin
mic
trovafloxacin
chang
phenotyp
highlevel
resist
occur
mic
grepafloxacin
moxifloxonli
mutat
parc
grla
acin
mic
gatifloxacin
mic
b
gyrab
gene
gyra
may
primari
levofloxacin
mic
target
fluoroquinolon
bacteria
data
vitro
assay
show
singlestep
ciprofloxacin
mic
intrins
mutat
occur
aureu
pneumonia
activ
compound
combin
frequenc
often
rang
pharmacokinet
profil
may
key
thu
singlestep
lowlevel
resist
varstand
abil
thwart
foster
emeri
probabl
common
mani
pulmonari
ingenc
resist
see
discuss
pharmacodyfect
sinc
bacteri
number
often
exnam
section
ceed
coloni
form
unit
cfu
g
tissu
insight
resist
seen
vitro
assay
variant
erad
second
mutat
predict
perform
fluoromay
lead
highlevel
resist
quinolon
clinic
practic
instanc
failur
resist
may
also
result
decreas
ciprofloxacin
cure
pneumococc
infect
outer
membran
permeabl
efflux
pump
well
document
tabl
sever
path
latter
energydepend
process
limit
tient
develop
mening
therapi
intracellular
accumul
antibacteri
clinic
trial
employ
ciprofloxacin
result
lowlevel
resist
may
may
treatment
aecb
pneumonia
found
occur
conjunct
mutat
topoisomerpersist
sputum
treat
patient
ase
gene
efflux
affect
activ
treatment
failur
due
organnorfloxacin
ciprofloxacin
levoflox
us
fda
subsequ
modifi
acin
gatifloxacin
gemifloxacin
activ
packag
insert
suggest
ciprofloxacin
moxifloxacin
trovafloxacin
affect
use
drug
first
choic
treatment
least
presum
confirm
pneumonia
due
pneumonia
failur
levofloxacin
also
import
differ
may
exist
abil
report
tabl
ii
ciprofloxacin
sevspecif
fluoroquinolon
select
resist
variant
eral
patient
develop
mening
among
gramposit
respiratori
pathogen
intherapi
lead
one
group
suggest
ciprofloxacin
select
resist
variant
lactam
drug
use
along
levofloxacin
pneumonia
vitro
readili
grepaflox
weiss
et
al
montreal
usa
kuehnert
et
al
georgia
levofloxacin
po
od
failur
aecb
acut
exacerb
chronic
bronchiti
bid
twice
daili
cap
communityacquir
pneumonia
copd
chronic
obstruct
pulmonari
diseas
f
femal
iv
intraven
male
nd
data
od
daili
po
oral
result
suscept
test
becom
availaresist
ciprofloxacin
howev
ble
note
mani
patient
studi
group
compar
isol
collect
fail
levofloxacin
therapi
previous
respiratori
season
collect
pose
fluoroquinolon
also
found
statist
signific
inport
other
failur
fluoroquicreas
levofloxacin
resist
nolon
report
date
may
tabl
iii
other
also
examin
occur
increas
use
drug
resist
newer
fluoroquinolon
among
pneumonia
instanc
brueggemann
et
al
exon
area
particular
concern
crossresist
amin
larg
group
isol
us
collectamong
fluoroquinolon
use
one
agent
ed
found
resislead
class
resist
fluoroquinolon
tanc
rate
levofloxacin
gatifloxacin
moxjohnson
note
isol
ifloxacin
low
remain
stabl
ciprofloxacin
mic
one
studi
doern
et
al
found
larg
number
also
resist
moxifloxacin
weiss
reportof
isol
resist
levofloxacin
ed
outbreak
fluoroquinoloneresist
chang
year
observ
pneumonia
hospit
ward
ciprofloxacin
thornsberri
sahm
found
result
often
use
empir
therapi
lower
respircompar
isol
collect
respiratori
atori
tract
infect
outbreak
involv
season
patient
organ
either
singl
parc
group
found
resist
levofloxacin
among
doubl
parc
gyra
mutat
lead
lowchildren
low
perhap
reflect
rel
level
highlevel
resist
lack
use
fluoroquinolon
populato
ciprofloxacin
respect
crossresist
tion
us
center
diseas
control
levofloxacin
mic
moxifloxacin
gaprevent
cdc
report
isol
recov
tifloxacin
mic
observ
anoth
studi
urban
cowork
report
two
painvas
pneumococc
diseas
found
tient
fail
levofloxacin
therapi
isol
ofloxacin
resist
increas
patient
increas
mic
increas
acin
moxifloxacin
trovafloxacin
data
levofloxacin
resist
interv
avail
prior
exposur
ciprofloxacin
sahm
et
al
report
slightli
higher
rate
report
mirror
crossresist
among
levofloxacin
resist
isol
collect
fluoroquinolon
seen
vitro
exposur
respiratori
season
analysi
isol
pneumonia
ciprofloxacin
rais
concollect
communitybas
practic
us
cern
misus
older
fluoroquinolon
may
instead
hospitalbas
laboratori
show
select
lowlevel
resist
variant
becom
resist
either
levofloxacin
gatifloxacin
highli
resist
fluoroquinolon
seckarchm
report
result
protekt
ond
mutat
us
prospect
resist
organ
track
epidemiolog
ketolid
telithromycin
although
resist
fluoroquinolon
unit
state
studi
isol
report
vitro
isol
patient
prevacollect
respiratori
season
lenc
resist
among
pneumonia
site
state
overal
levofloxacin
resisrespiratori
pathogen
larg
geograph
area
tanc
rate
low
vari
geograph
time
remain
low
tabl
iii
sahm
southeast
northeast
worker
first
examin
howev
resist
rate
higher
area
fluoroquinolon
resist
rate
among
respiratori
countri
rate
highest
massachusett
pathogen
report
colorado
alaska
pneumonia
isol
collect
year
ciprofloxacin
use
us
citi
salem
massachusett
stam
karlowski
et
al
johnson
et
al
england
surveil
nd
nd
wale
refer
nd
nd
glatz
et
al
ford
connecticut
dayton
ohio
worker
examin
almost
pneumonia
denver
colorado
isol
collect
throughout
canada
found
resist
fluoroquinolon
resist
trend
also
levofloxacin
howev
note
crossresisexamin
countri
longitudin
studi
tanc
among
fluoroquinolon
common
canada
chen
et
al
report
preval
ciprofloxacinresist
pneumonia
isol
resist
levofloxacin
instrain
increas
creas
mic
ciprofloxacin
gatifloxacin
moxiand
seen
commonli
adult
floxacin
gemifloxacin
garenoxacin
powi
children
reflect
use
fluoroquicowork
examin
isol
collect
nolon
canada
resist
newer
part
canadian
bacteri
surveil
network
fluoroquinolon
remain
low
zhanel
coin
report
levofloxacin
resist
rate
increas
report
tekt
surveil
studi
around
except
hong
kong
year
isol
resist
two
antibacterian
analysi
pneumonia
strain
colal
similar
high
resist
rate
hong
kong
lect
austria
show
also
report
ho
colleagu
levofloxacin
resist
rare
summari
resist
pneumonia
readili
resist
moxifloxacin
gatifloxacin
select
vitro
failur
among
patient
uk
johnson
et
al
found
high
preval
treat
ciprofloxacin
levofloxacin
moxifloxacin
resist
among
isol
refer
well
document
howev
date
resist
addit
test
resist
firstlin
rate
newer
fluoroquinolon
among
pneuagent
preval
resist
much
monia
appear
low
although
sever
studi
lower
among
isol
collect
routin
surveilsuggest
rate
increas
localis
area
lanc
activ
glatz
cowork
hunth
world
studi
shown
fluoroquinolon
gari
also
found
higher
rate
fluoroquinolon
resist
common
among
person
levofloxacin
resist
among
isol
year
age
contrast
penicillin
resist
resist
agent
case
penicillin
common
children
may
reflect
low
level
resist
newer
fluoroquith
rel
use
antibacteri
age
nolon
report
sever
small
colgroup
may
chang
fluoroquinolon
lection
isol
european
countri
approv
paediatr
use
crossresist
among
rel
low
level
levofloxacin
resist
fluoroquinolon
seen
conwa
report
small
seri
taiwan
cern
thu
overus
older
agent
may
result
song
et
al
report
resist
rate
loss
efficaci
newer
agent
also
note
pneumonia
isol
collect
asian
counfluoroquinolon
resist
isol
often
resist
tri
respiratori
season
reto
class
antibacteri
well
port
resist
higher
levofloxacin
among
organ
resist
levofloxacin
reand
gatifloxacin
moxifloxacin
port
cdc
also
resist
sever
larg
studi
attempt
monitor
penicillin
resist
cefotaxim
preval
fluoroquinolon
resist
among
resist
erythromycin
resiss
pneumonia
worldwid
instanc
sahm
tant
cotrimoxazol
trimethoprimsulfamethoxcowork
report
larg
number
isol
azol
similar
trend
report
collect
china
japan
sever
european
other
h
influenza
report
countri
winter
found
resist
ciprofloxacin
date
h
influenza
low
preval
resist
levofloxacin
among
catarrhali
remain
sensit
pneumonia
hoban
et
al
report
data
newer
fluoroquinolon
sentri
antimicrobi
surveil
program
found
low
worldwid
preval
resist
pharmacokinet
levofloxacin
gatifloxacin
howev
pharmacodynam
consider
data
north
america
examin
trend
resist
found
rate
resist
efficaci
antibacteri
pathogen
levofloxacin
among
pneumonia
increas
often
express
term
mic
mic
anoth
defin
concentr
antibacteri
studi
resist
common
asiaresult
net
growth
inoculum
pacif
region
follow
north
bacteria
incub
hour
laboratori
america
europ
latin
america
techniqu
determin
mic
well
worldwid
preval
resisinterpret
breakpoint
use
label
organt
levofloxacin
moxifloxacin
proism
sensit
intermedi
resist
antibacteri
publish
current
use
clinic
laboratori
although
mic
use
success
manag
patient
past
statist
prove
limit
valu
predict
emerg
resist
fluoroquinolon
recent
investig
focus
effect
antibacteri
select
resist
variant
propos
environ
provid
small
differ
antibacteri
concentr
could
select
effect
bacteri
cultur
compris
subpopul
heterogen
resist
phenotyp
select
window
compart
bound
concentr
inhibit
suscept
bacteria
mic
concentr
inhibit
organ
lowlevel
resi
mic
mpc
propos
predict
tanc
negri
cowork
examin
effect
fluoroquinolon
bacteri
kill
effect
antibacteri
exposur
mixtur
penth
emerg
resist
common
icillinsuscept
resist
pneumonia
pharmacokinet
valu
examin
peak
escentr
antibacteri
dose
cmax
cherichia
coli
differ
mic
show
area
concentrationtim
resist
strain
readili
select
curv
experiment
evid
shown
antibacteri
concentr
within
select
mani
case
quinolon
kill
rapidli
compart
concentr
appreci
dong
colleagu
suggest
similar
mic
target
microorgan
known
principl
govern
select
resist
variant
concentrationdepend
dosedepend
kill
aureu
expos
fluoroquinolon
de
contrast
timedepend
concentrationinfin
mutant
select
window
antimicrodepend
kill
often
seen
bial
concentr
rang
fall
mic
macrolid
effort
made
quantifi
mutant
prevent
concentr
mpc
relationship
pharmacokinet
param
concentr
inhibit
growth
firststep
ter
cmax
pharmacodynam
pamut
figur
report
experiment
data
ramet
mic
optimis
dose
administr
stratand
theoret
analys
suggest
regimen
egi
date
clinic
trial
provid
fluoroquinolon
concentr
fall
examin
ratio
use
mpc
divisor
within
select
window
select
resist
aureu
strain
wherea
regimen
provid
concentra
valu
pharmacodynam
ratio
tion
mpc
prevent
emerg
mic
cmaxmic
predict
outcom
resist
strain
work
expandfluoroquinolon
therapi
examin
ed
theoret
analysi
effect
fluorostudi
forrest
cowork
analys
result
quinolon
pneumonia
date
ciprofloxacin
therapi
serious
ill
patient
exact
relationship
pharmacokinet
profil
varieti
infect
conclud
bacteri
mic
mpc
delimit
mic
ratio
import
predictor
select
window
defin
clinic
microbiolog
cure
applic
conclus
lowerrespiratori
tract
infeca
number
pharmacokinet
paramet
tion
uncertain
howev
infect
relationship
pharmacodynam
paramet
wound
urinari
tract
includ
pathogen
caus
respiratori
skin
urinari
tract
analysi
patient
infect
infect
treat
levofloxacin
preston
pneumonia
major
patient
infectcowork
conclud
clinic
microbi
aureu
p
aeruginosa
gramolog
outcom
like
favour
neg
aerob
conclus
studi
reif
cmaxmic
ratio
gard
efficaci
ciprofloxacin
may
also
other
examin
pharmacodynam
ratio
confound
concomit
use
rifampin
specif
fluoroquinolon
pneumoniand
azlocillin
patient
investigaa
laci
et
al
studi
effect
ciprofloxtor
later
examin
effect
three
differ
oral
acin
levofloxacin
four
isol
grepafloxacin
dose
patient
aecb
vitro
infect
model
found
bacteri
patient
infect
wide
varieti
gramgrowth
suppress
levofloxacin
neg
gramposit
bacteria
vari
ratio
rang
regrowth
ceptibl
antibacteri
author
occur
ciprofloxacin
highest
analys
aggreg
data
conclud
ratio
test
anoth
vitro
valu
inadequ
model
lister
sander
show
levofloxvalu
suffici
bacteriolog
acin
erad
eight
strain
auc
raand
clinic
cure
howev
valu
tio
rang
ciprofloxacin
eradiassoci
bacteriolog
clinic
cure
vacat
five
strain
valu
rie
organ
examin
instanc
craig
and
examin
effect
grepafloxacinsensit
organ
catarfluoroquinolon
pneumonia
murin
rhali
haemophilu
spp
erad
rethigh
infect
model
found
gardless
valu
pneumonia
isol
kill
organ
surcat
valu
vival
studi
respect
contrast
examin
effect
levofloxacin
gatifloxacin
resist
organ
p
aeruginosa
patient
cap
aecb
caus
erad
lowest
rang
pneumonia
ambros
et
al
found
bacteriand
erad
highest
al
erad
freedrug
ratio
rang
anoth
studi
perform
patient
ceiv
ciprofloxacin
nosocomi
overal
data
clinic
trial
limit
lowerrespiratori
tract
infect
conclud
cuand
conclus
trial
confus
like
clinician
studi
suggest
howev
applic
conclus
gener
higher
cmaxmic
ratio
patient
pneumonia
catarrhali
infeceith
result
dose
administr
sustion
remain
uncertain
patient
ceptibl
organ
lead
better
outstudi
infect
organ
anothcom
exact
valu
pharmacody
studi
analys
data
trial
namic
ratio
target
rapid
kill
levofloxacin
sometim
drug
adminisor
prevent
resist
remain
elus
probabl
tere
treatment
nosocomi
pneumonia
wide
varieti
organ
andu
rang
gramposit
neg
bactetibacteri
studi
limit
number
isol
ria
conclud
aucmic
ratio
optitest
use
differ
system
vitro
mal
erad
pathogen
involv
anim
clinic
trial
systemat
aponli
one
trial
examin
abil
cmax
proach
use
limit
number
organ
mic
ratio
predict
outcom
fluoroquinolon
tightli
control
condit
might
use
therapi
basi
result
larg
multicentr
trial
involv
patient
varieti
gain
insight
broad
pharmacodynam
principl
could
appli
tightli
congemifloxacin
moxifloxacin
garenoxacin
troll
clinic
trial
activ
ciprofloxacin
pathogen
pneumonia
aureu
appear
new
insight
evolut
resist
less
propens
select
resist
variant
among
bacteria
expos
fluoroquinolon
use
clinic
dose
administr
regimen
use
novel
dose
administr
regimen
vitro
system
may
newer
fluorobeen
gain
seri
experi
quinolon
better
pharmacokinet
profil
vitro
pharmacodynam
system
experithan
older
agent
higher
cmaxmpc
ment
aureu
expos
simul
clinic
mpc
ratio
properti
intrins
experiment
regimen
ciprofloxacin
compound
increas
activirespons
bacteria
monitor
time
ty
lower
mic
mpc
sever
newer
exposur
clinic
regimen
twice
fluoroquinolon
moxifloxacin
may
allow
three
time
daili
initi
sensit
bacteria
clinician
exceed
mpc
without
produc
becam
resist
evidenc
chang
toxic
mic
observ
whenev
bacteria
grown
high
number
pharmacokinet
paramet
comfor
inoculum
system
cfu
small
monli
encount
fluoroquinolon
market
number
bacteria
lowlevel
resist
mic
present
tabl
iv
potenti
imin
rang
would
invari
portant
differ
among
agent
inpres
appear
result
spontan
stanc
halflif
newer
fluoroquimut
qrdr
grla
mani
case
mathnolon
rang
hour
c
max
emat
model
bacteri
kill
regrowth
vari
system
function
dose
administr
steadi
state
vari
mg
h
done
model
use
predict
l
controversi
exist
valu
beregimen
would
erad
cultur
regicaus
investig
believ
drug
men
consist
singl
high
dose
erad
protein
bound
biolog
activ
lowlevel
resist
variant
present
inoculum
protein
bind
taken
account
cmax
valu
follow
standard
dose
administr
eradisom
compound
gemifloxacin
garec
sensit
major
regimen
noxacin
must
reduc
respectest
vitro
system
cultur
eradit
contrast
investig
cate
experi
suggest
key
shown
protein
bind
littl
effect
bacteri
erad
target
lowlevel
resisfluoroquinolon
activ
fact
tant
variant
present
inoculum
compound
concentr
alveolar
macrophag
rang
serum
cmax
strategi
fit
well
concept
ciprofloxacin
gatifloxacin
mpc
concentr
antibacteri
bronchial
epitheli
fluid
rang
prevent
appear
firststep
mutant
serum
cmax
ciprofloxacin
shown
pharmacokinet
profil
moxifloxacin
may
import
clinic
howevkeep
antibacteri
concentr
mpc
er
data
must
interpret
context
prevent
select
resist
variant
ultith
mic
mpc
pathogen
like
enmat
lead
bacteri
erad
vitro
syscount
lower
respiratori
tract
infect
tem
howev
exact
relationship
ciprofloxacin
newer
fluoroquinolon
pharmacokinet
profil
mpc
yet
compar
basi
pharmacokinet
elucid
simpli
keep
concentr
anparamet
cmax
standard
dose
tibacteri
mpc
may
result
unacceptadministr
regimen
mic
mpc
abl
toxic
mention
earlier
newer
fluoroquinolon
levofloxacin
gatifloxacin
larg
collect
pneumonia
becom
evid
ratio
differ
consider
among
fluoroquinolon
tabl
v
instanc
valu
rang
valu
rang
ciprofloxacin
gemifloxacin
respect
similar
differ
appar
mpc
use
divisor
ratio
calcul
alveolar
macrophag
bronchial
epitheli
line
fluid
present
interpret
valu
applic
patient
care
yet
clarifi
gener
higher
pharmacodynam
ratio
serum
alveolar
macrophag
epitheli
line
fluid
probabl
lead
less
select
resist
better
patient
outcom
exact
valu
delimit
probabl
cure
failur
remain
defin
zhanel
et
al
review
four
studi
publish
prior
first
quarter
levofloxacin
dosag
day
compar
cefuroxim
axetil
cefaclor
treatment
aecb
bacteri
erad
rate
levofloxacin
rang
clinic
success
rate
rang
clinic
success
rate
cephalosporin
rang
four
studi
publish
sinc
review
compar
efficaci
levofloxacin
agent
tabl
vi
masterton
burley
compar
cours
oral
levofloxacin
patient
aecb
centr
ten
countri
found
equival
clinic
microbiolog
success
regimen
weiss
examin
rel
efficaci
levofloxacin
clarithromycin
cefuroxim
axetil
patient
aecb
efficaci
toler
three
agent
similar
case
file
et
al
report
result
studi
compar
levofloxacin
enhanc
amoxicillinclavulan
acid
formul
design
treatment
penicillinresist
pneumonia
regimen
ciprofloxacin
levofloxacin
gatifloxacin
moxifloxacin
gemifloxacin
success
erad
pneumonia
sputum
cure
patient
amsden
cowork
studi
patient
recruit
medic
centr
us
august
may
show
equival
azithromycin
levofloxacin
success
rate
endpoint
clinic
cure
improv
aecb
number
small
show
differ
rate
bacteri
erad
drug
equal
well
toler
fogarti
colleagu
summaris
result
four
studi
commiss
r
w
johnson
pharmaceut
research
institut
raritan
new
jersey
studi
efficaci
levofloxacin
cap
caus
erythromycinsensit
resist
pneumonia
tabl
vi
studi
independ
report
result
one
studi
comment
upon
previou
review
levofloxacin
efficaci
overal
microbiolog
clinic
success
good
respect
differ
among
patient
infect
erythromycinsensit
resist
organ
anoth
studi
report
fogarti
et
al
levofloxacin
compar
ceftriaxon
plu
erythromycin
given
intraven
follow
amoxicillinclavulan
acid
plu
clarithromycin
given
oral
overal
clinic
success
rate
bacteria
erad
rate
compar
gotfri
cowork
examin
rel
efficaci
oral
levofloxacin
extendedreleas
formul
clarithromycin
ambulatori
patient
cap
agent
appear
equal
efficaci
microbiolog
erad
rate
case
clinic
cure
improv
seen
patient
frank
cowork
compar
levofloxacin
combin
regimen
ceftriaxon
azithromycin
patient
hospitalis
moderatetosever
cap
regimen
given
least
day
although
ceftriaxon
administ
first
day
prevent
bacteraemia
due
pneumonia
regimen
hansen
et
al
mpc
valu
hansen
et
al
b
free
drug
c
ratio
calcul
use
cmax
obtain
singl
oral
dose
ratio
calcul
use
cmax
obtain
singl
oral
dose
hour
follow
ciprofloxacin
po
everi
hour
day
bid
twice
daili
db
doubleblind
dd
doubl
dummi
im
intramuscular
iv
intraven
mc
multicentr
nb
nonblind
nd
data
od
daili
p
prospect
pl
parallel
po
oral
r
randomis
equal
efficaci
bacteri
erad
caci
trovafloxacin
clinic
bacteriologiand
clinic
cure
improv
rate
exceed
cal
success
rate
gemifloxacin
multicentr
postmarket
assessversu
trovafloxacin
ment
levofloxacin
efficaci
treatment
author
also
review
preliminari
result
cap
akpunonu
cowork
report
excelglob
gemifloxacin
long
term
outcom
lent
success
varieti
respiratori
pathobronch
exacerb
studi
efficagen
cy
safeti
cours
gemifloxacin
compar
standard
regimen
clarithromycin
patient
aecb
tabl
one
clinic
trial
publish
vii
clinic
bacteriolog
cure
rate
examin
efficaci
one
new
respiratori
compar
group
howev
imfluoroquinolon
nosocomi
pneumonia
pact
treatment
longterm
week
trial
compar
high
dose
levofloxacin
clinic
outcom
assess
significantli
given
intraven
oral
imipenem
patient
receiv
gemifloxacin
clarithromycin
cilastatin
follow
oral
ciprofloxacin
anremain
free
aecb
recurr
vs
tibacteri
could
ad
patient
respect
ed
p
aeruginosa
mrsa
clinic
cure
sinc
review
zhanel
et
al
least
four
microbiolog
erad
rate
similar
studi
publish
address
use
tabl
vi
gemifloxacin
aecb
compar
convent
antibacteri
regimen
tabl
amoxicillinclavulan
acid
treatment
zhanel
et
al
review
result
two
patient
aecb
randomis
doubleport
use
gemifloxacin
aecb
first
blind
multicentr
studi
two
drug
compawa
randomis
doubleblind
multin
studi
rabl
clinic
cure
rate
although
microthat
compar
efficaci
safeti
gemifloxbiolog
efficaci
penicillin
regimen
acin
trovafloxacin
treatment
somewhat
less
recent
wilson
coaecb
gemifloxacin
demonstr
similar
effiwork
compar
use
oral
gemifloxacin
given
daili
day
intraven
cefwa
also
compar
signific
differtriaxon
follow
oral
cefuroxim
axetil
given
enc
incid
type
advers
drug
maximum
day
treatment
effect
none
patient
studi
hospitalis
patient
aecb
clinic
sucqtc
interv
chang
outsid
normal
cess
rate
followup
day
posttherapi
rang
anoth
openlabel
noncompar
clinic
perprotocol
popul
signifistudi
ball
et
al
assess
clinic
bactecantli
higher
gemifloxacin
ceftriaxon
riolog
efficaci
gemifloxacin
aecb
cefuroxim
studi
differ
ci
correor
gemifloxacin
oral
levofloxacin
spond
clinic
result
intentiontotreat
adult
medic
centr
us
uk
popul
versu
germani
found
clinic
respons
respect
treatment
differ
ci
safeti
two
drug
regimen
drug
compar
nb
nc
mc
gemifloxacin
po
od
day
overal
sethi
et
al
r
db
dd
gemifloxacin
po
od
day
nd
mc
pl
levofloxacin
po
od
day
lode
et
al
dd
pl
amoxicillinclavuan
tid
day
bid
twice
daili
c
compar
db
doubleblind
dd
doubledummi
globe
gemifloxacin
long
term
outcom
bronchiti
exacerb
iv
intraven
mc
multicentr
nb
nonblind
nc
noncompar
nd
data
od
daili
pl
parallel
group
po
oral
r
randomis
tid
three
time
daili
short
gatifloxacin
cours
result
clinic
zhanel
et
al
review
result
studi
cure
rate
compar
longer
gafil
et
al
compar
efficaci
gemifloxtifloxacin
clarithromycin
cours
microbiacin
trovafloxacin
treatment
cap
olog
erad
rate
report
evalu
demonstr
similar
efficaci
treatment
group
anoth
group
assess
clinic
microbiolog
three
efficaci
toler
gatifloxacin
openstudi
subsequ
publish
examinlabel
noncompar
postmarket
trial
overal
ing
use
gemifloxacin
cap
tabl
vii
clinic
cure
demonstr
lode
cowork
compar
use
oral
patient
nicholson
et
al
found
gemifloxacin
sequenti
therapi
intraveclin
cure
rate
patient
age
rang
nou
ceftriaxon
oral
cefuroxim
year
old
macrolid
treatment
patient
hospitalis
cap
randomis
openlabel
multi
centr
studi
clinic
bacteriolog
three
randomis
doubleblind
trial
compar
efficaci
oral
gemifloxacin
high
efficaci
gatifloxacin
ceftriaxon
compar
regimen
withwithout
erythromycin
clarithromycin
levofloxout
macrolid
ball
cowork
found
acin
patient
cap
review
previthat
gemifloxacin
achiev
clinic
microbio
trial
gatifloxacin
achiev
slightlog
success
subset
patient
cap
ly
better
clinic
cure
bacteriolog
erad
leophont
et
al
randomis
patient
rate
vs
compar
compar
cap
medic
centr
franc
poland
vs
respect
least
seven
south
africa
either
gemifloxacin
oral
day
studi
address
use
gatifloxacin
day
amoxicillinclavulan
acid
oral
cap
sinc
publish
tabl
viii
franca
day
clinic
cure
rate
group
carvalho
casilla
cowork
demonstr
clinic
cure
rate
nicholson
et
al
evalu
gatifloxacin
elderli
zhanel
et
al
review
analysi
ramirez
patient
found
good
clinic
success
rate
cowork
result
two
pneumonia
infect
well
bacteri
randomis
doubleblind
studi
one
nonerad
rate
less
effect
blind
studi
evalu
efficaci
gatifloxacin
patient
year
old
anoth
studi
treatment
aecb
pool
clinic
report
author
clinic
cure
rate
bacteriolog
cure
rate
seen
gatifloxacin
regardless
age
bacteriologiwer
compar
either
levofloxacin
cefuroxc
erad
rate
document
presum
ime
axetil
vs
vs
clinic
pneumonia
data
given
h
bacteriolog
cure
respect
howinfluenza
gotfri
et
al
report
result
ever
superior
bacteriolog
erad
rate
teqc
communitybas
openlabel
proagainst
pneumonia
h
influenza
seen
spectiv
noncompar
studi
oral
gatifloxacin
gatifloxacin
versu
compaus
outpati
cap
drug
achiev
clinic
rator
respect
microbiolog
cure
rate
two
larg
three
studi
address
use
gatifloxacin
trial
lode
et
al
demonstr
therapeuin
aecb
publish
recent
tabl
viii
tic
equival
oral
gatifloxacin
either
one
group
compar
gatifloxacin
gaclarithromycin
amoxicillinclavulan
acid
tifloxacin
clarithromycin
cours
moxifloxacin
rather
serolog
unfortun
c
pneumonia
could
recov
nasopharyng
secret
enrol
patient
five
addit
patient
elimin
two
studi
recent
review
analysi
followup
cultur
done
moxifloxacin
mgday
compar
treatment
small
number
patient
clarithromycin
treatment
aecb
treat
clarithromycin
appear
efficaclin
success
rate
moxifloxacin
rang
ciou
moxifloxacin
although
number
clinic
success
rate
small
formal
statist
comparison
clarithromycin
rang
five
mani
patient
coinfect
studi
publish
sinc
review
compneumonia
h
influenza
bacteria
pare
efficaci
moxifloxacin
agent
petitpretz
cowork
compar
efficaci
tabl
ix
deabat
et
al
report
result
moxifloxacin
highdos
amoxicillin
larg
clinic
trial
involv
centr
us
mgday
patient
cap
larg
studi
inwher
moxifloxacin
compar
azithrovolv
centr
countri
found
mycin
agent
produc
excel
erad
rate
key
respiratori
tract
pathogen
correboth
agent
gave
good
result
although
bacteri
spondingli
high
clinic
cure
success
rate
erad
rate
clinic
cure
rate
slightli
author
conclud
cours
moxifloxhigh
fluoroquinolon
frequenc
acin
equival
azithromycin
aecb
advers
effect
also
compar
schaberg
et
al
report
find
larg
group
anoth
larg
multin
multicentri
involv
centr
countri
compar
tre
studi
carri
hoeffken
et
al
moxifloxacin
one
tablet
daili
day
compar
efficaci
two
dose
moxifloxacin
therapi
amoxicillinclavulan
acid
mgday
clarithromycin
three
tablet
daili
day
overal
twice
day
regimen
well
toler
patient
well
either
regimen
miravitl
discontinu
rate
overal
cowork
follow
spanish
patient
clinic
cure
rate
approxim
aceb
moxifloxacin
found
three
regimen
higher
moxifloxacin
dosag
assess
patient
cure
week
regimen
slightli
superior
erad
pathotherapi
advers
effect
low
gen
either
regimen
italian
studi
grassi
cowork
found
finch
cowork
examin
rel
oral
daili
moxifloxacin
equal
efficaci
efficaci
moxifloxacin
penicillin
plu
daili
administr
intramuscular
ceftriaxon
macrolid
regimen
patient
cap
therapeut
equival
moxifloxacin
ill
enough
requir
parenter
therapi
intraven
amoxicillinclavulan
acid
demonstr
moxifloxacin
switch
oral
therapi
soon
staraki
et
al
possibl
mandatori
period
given
addit
day
regimen
compar
highdos
amoxicillinclavulan
acid
two
previous
review
studi
examin
initi
given
intraven
least
day
efficaci
moxifloxacin
mgday
treatand
switch
oral
administr
clarithro
cap
clinic
success
rate
mycin
could
ad
discret
five
studi
publish
sinc
ing
physician
cover
atyp
pathogen
although
review
tabl
ix
hammerschlag
roblin
diagnos
serolog
attempt
assess
rel
efficaci
moxth
patient
enrol
overal
moxifloxacin
ifloxacin
clarithromycin
treatment
therapi
superior
penicillin
plu
macrolid
cap
caus
c
pneumonia
unlik
studregimen
term
rate
clinic
bacteriolog
defin
infect
basi
cultur
age
group
n
anzueto
nb
nc
casilla
nb
nc
mc
gatifloxacin
po
od
day
nd
nicholson
nc
mc
gatifloxacin
po
od
day
overal
overal
et
al
pneumonia
lode
et
al
catarrhali
bid
twice
daili
db
doubleblind
dd
doubledummi
mc
multicentr
nb
nonblind
nc
noncompar
nd
data
od
daili
p
prospect
po
oral
r
randomis
tid
three
time
daili
ical
cure
time
resolut
fever
vs
day
involv
centr
throughout
world
torr
et
proport
patient
switch
oral
therapi
al
compar
oral
moxifloxacin
either
within
day
vs
length
hospit
amoxicillin
clarithromycin
given
stay
vs
day
larg
trial
day
seventeen
percent
compar
group
receiv
amoxicillin
alon
receiv
um
confus
psychosi
abnorm
vision
clarithromycin
alon
receiv
drug
rare
seizur
seizur
may
encount
clinic
success
rate
test
regimen
often
quinolon
use
treat
patient
approxim
moxifloxacin
better
tolera
histori
stroke
seizur
disord
ate
compar
regimen
therapati
potenti
epileptogen
medicapeut
equival
moxifloxacin
combin
nsaid
theophyllin
concomit
ceftriaxon
azithromycin
metronidazol
tantli
administ
cn
advers
effect
patient
initi
requir
intraven
therapi
overal
incid
common
cap
shown
katz
cowork
trovafloxacin
least
common
levofloxacin
gemifloxacin
summari
clinic
trial
dermatolog
overal
newer
fluoroquinolon
often
achiev
clinic
cure
rate
patient
dermatolog
advers
effect
includ
rash
pruaecb
cap
rate
may
lower
hap
ritu
photosensit
hyperpigment
urticlin
trial
gatifloxacin
gemifloxacin
moxicaria
phototox
link
primarili
floxacin
nosocomi
pneumonia
pubpres
halogen
atom
posit
lish
date
compar
clinic
trial
quinolon
nucleu
compound
sparfloxkind
report
garenoxacin
acin
clinafloxacin
substitut
methyl
studi
review
littl
differ
group
posit
gatifloxacin
clinic
success
rate
fluoroquinolon
commoxifloxacin
significantli
reduc
pare
macrolid
test
phototox
potenti
dermatolog
advers
effect
rang
incid
advers
drug
effect
seen
often
clinafloxacin
sparfloxacin
taken
market
least
often
current
market
us
fdaapprov
quiwith
trovafloxacin
gatifloxacin
moxifloxnolon
consid
rel
safe
well
acin
recent
us
fdaapprov
toler
howev
like
class
drug
fluoroquinolon
gemifloxacin
inciadvers
effect
may
encount
tabl
x
denc
rash
occur
commonli
among
gastrointestin
cn
effect
frewomen
year
age
quent
advers
event
musculoskelet
advers
effect
includ
arthropgastrointestin
advers
effect
includ
alter
athi
chondrotox
tendon
tendon
ruptast
anorexia
nausea
vomit
diarrhoea
ture
arthropathi
chondrotox
mainli
effect
rang
incid
acbeen
shown
immatur
laboratori
anim
cord
quinolon
use
common
seem
rare
human
perhap
trovafloxacin
overal
rate
among
limit
use
agent
among
children
howevth
newer
fluoroquinolon
similar
aler
arthralgia
arthriti
report
occur
though
nausea
vomit
diarrhoea
may
incid
children
higher
moxifloxacin
gatifloxacin
comjuvenil
treat
ciprofloxacin
pare
levofloxacin
hand
case
report
tendon
ruptur
achil
tendon
use
ciprofloxacin
ofloxacin
norfloxacin
levofloxcn
advers
effect
includ
dizzi
headach
acin
risk
factor
tendinopathi
insomnol
less
commonli
agit
deliriclud
renal
failur
corticosteroid
use
hammerschlag
r
db
moxifloxacin
po
od
day
chlamydophila
pneumonia
roblin
clarithromycin
po
bid
day
c
pneumonia
ceftrixon
iv
azithromycin
iv
overal
od
metronidazol
iv
everi
pneumonia
hour
switch
cefuroxim
po
h
influenza
bid
azithromycin
po
od
metronidazol
po
everi
hour
bid
twice
daili
db
doubleblind
im
intramuscular
iv
intraven
mc
multicentr
nb
nonblind
nc
noncompar
nd
data
od
daili
p
prospect
po
oral
r
randomis
tid
three
time
daili
studi
anoth
studi
demoli
cowork
compar
effect
moxifloxacin
fluoroquinolon
caus
hypotens
versu
placebo
qtc
intertachycardia
prolong
qtc
interv
healthi
men
women
doubleblind
val
latter
effect
although
rare
encounrandomis
placebocontrol
crossov
studi
tere
may
lead
cardiac
arrhythmia
patient
ecg
record
rest
exercis
hypokalaemia
underli
heart
diseas
mean
sd
receiv
antiarrhythm
drug
increas
rel
placebo
two
dose
across
prolong
qtc
interv
quinidin
proa
wide
rang
rr
interv
although
cainamid
disopyramid
sotalol
amiodaron
chang
statist
signific
author
recent
doubleblind
randomis
fourperiod
conclud
risk
moxifloxacininduc
torfourtreat
foursequ
crossov
trial
comsad
de
point
would
low
moxifloxacin
pare
effect
placebo
levofloxacin
howev
advis
caution
use
moxifloxacin
ciprofloxacin
drug
patient
predispos
factor
qtc
interv
prolong
drug
dose
torsad
de
point
electrolyt
disturb
twice
recommend
us
fda
routin
bradycardia
coadministr
clinic
use
increas
qt
qtc
interv
comproarrhythm
drug
qtc
interv
prolong
pare
placebo
statist
signific
also
report
sparfloxacin
three
antibacteri
consist
greater
grepafloxacin
remov
moxifloxacin
placebo
market
either
levofloxacin
blood
pressur
chang
includ
hypertens
ciprofloxacin
howev
advers
effect
experienc
volunt
hypotens
postur
hypotens
tabl
x
advers
drug
effect
quinolon
antibacteri
drug
gastrointestin
cn
dermatolog
musculoskelet
cardiovascular
idiosyncrat
reaction
moxifloxacin
gemifloxacin
nd
nd
nd
data
indic
rel
incid
lowest
highest
report
incid
use
summari
advers
drug
effect
current
market
quinolon
histamin
releas
postul
one
summari
current
market
fluoroquirespons
mechan
hypotens
sever
nolon
appear
safe
well
toler
class
hypotens
may
occur
singl
dose
drug
although
sever
compound
either
current
restrict
quinolon
trovafloxacin
withdrawn
market
temafloxacin
mention
section
hypotens
occur
restrict
trovafloxacin
never
releas
sparmor
new
quinolon
garenoxacin
floxacin
grepafloxacin
perhap
garenoxacin
compar
phase
iii
trial
common
advers
effect
gastrointestin
overal
rate
low
discontinua
tion
rate
among
newer
fluoroquinolon
perhap
advers
effect
gatifloxacin
shown
mark
concern
prolong
qtc
interv
effect
glucos
toler
pancreat
funcsinc
lead
danger
arrhythmia
protion
howev
caus
brief
increas
serum
longat
appear
greatest
moxifloxacin
insulin
level
sever
persist
hypoglyunfortun
known
threshold
qt
caemia
caus
gatifloxacin
interact
oral
interv
prolong
arrhythmia
hypoglycaem
agent
report
least
three
occur
known
safe
case
report
ciprofloxacin
may
also
caus
slight
known
postmarket
trial
ciprofloxfluctu
blood
sugar
level
patient
receivacin
levofloxacin
arrhythmia
occur
rate
ing
oral
hypoglycaem
drug
less
one
per
million
patient
whether
rate
higher
gatifloxacin
gemifloxacin
moxifloxacin
known
idiosyncrat
reaction
drug
use
extens
interest
qtc
interv
prolong
report
numther
report
asymptomat
ber
antimicrobi
includ
macrolid
symptomat
hepat
pancreat
sever
hepatoand
imidazol
toxic
death
associ
trovafloxacin
note
earlier
us
fda
advis
restrict
use
drug
patient
lifeor
import
drug
interact
ene
infect
clinician
advis
monitor
serum
transaminas
indic
hepatobilioth
drug
may
alter
serum
fluoroquinolon
ari
function
patient
receiv
hepat
concentr
fluoroquinolon
may
alter
metabolis
quinolon
trovafloxacin
moxifloxacin
metabol
multival
cation
iron
zinc
calcium
acut
bronchiti
aluminium
magnesium
may
form
insolubl
use
antibacteri
acut
bronchiti
complex
oral
administ
fluoroquidiscourag
aetiolog
often
nolon
gastrointestin
tract
decreas
viral
use
antibacteri
syndrom
absorpt
antibacteri
exampl
result
unnecessari
cost
advers
drug
effect
drug
includ
multivitamin
miner
potenti
select
resist
bactesuppl
antacid
sucralf
ria
clinic
evalu
radiograph
drug
necessari
administ
imag
microbiolog
studi
carleast
hour
hour
oral
administrari
patient
present
sugtion
fluoroquinolon
avoid
interact
gest
seriou
ill
pneumonia
antiretrovir
drug
didanosin
also
impair
abthos
sever
prolong
durat
ill
sorption
quinolon
drug
formul
antibacteri
may
use
underli
bactericontain
calcium
carbon
magnesium
hydrox
aetiolog
found
case
macrolid
ide
buffer
probenecid
loop
diuret
tetracyclin
may
appropri
fluoroquinolon
cimetidin
increas
serum
fluoroquinolon
conshould
reserv
secondlin
agent
patient
centrat
resist
bacteria
follow
local
trend
antibacteri
resist
may
valu
quinolon
inhibit
cytochrom
syssever
guidelin
address
manag
tem
lead
increas
serum
concentr
aecb
publish
stratif
drug
theophyllin
caffein
digoxin
patient
allow
identif
patient
high
risk
infect
resist
bacteria
treatciclosporin
cyclosporin
warfarin
newer
ment
failur
complic
cours
highrisk
fluoroquinolon
levofloxacin
gatifloxacin
factor
includ
signific
impair
lung
funcand
moxifloxacin
less
effect
theophylt
four
episod
line
pharmacokinet
older
agent
fluoroquiof
aecb
per
year
oral
corticosteroid
use
age
nolon
use
caution
patient
year
comorbid
condit
diabet
receiv
class
ia
procainamid
quinidin
dismellitu
heart
diseas
renal
failur
paopyramid
class
iii
amiodaron
bretylium
tient
aggress
approach
includ
sputum
sotalol
dofetilid
ibutilid
antiarrhythm
drug
gramstain
cultur
initi
empir
well
erythromycin
cisaprid
antipsychot
use
broadspectrum
antibacteri
justifi
tricycl
antidepress
prolong
qtc
avoid
treatment
failur
interv
increas
potenti
fatal
decid
whether
use
fluoroquinolon
tachyarrhythmia
concurr
use
cortior
altern
class
antibacteri
patient
costeroid
may
increas
risk
tendon
ruptur
aecb
help
inform
especi
elderli
patient
local
bacteri
resist
rate
unfortun
data
fluoroquinolon
gatifloxacin
often
avail
larg
nation
lesser
extent
ciprofloxacin
interact
oral
hypointern
survey
may
differ
depend
upglycaem
agent
may
result
seriou
hypoon
sourc
isol
hospit
vs
communiglycaemia
ty
instanc
one
larg
studi
hospit
isol
collect
us
ation
cephalosporin
eg
ceftazidim
cefepim
aminoglycosid
p
aeruginosa
suspectrespiratori
season
h
influenza
ed
sputum
cultur
result
antibacteri
strain
resist
ampicillin
sensit
data
avail
one
author
resist
cotrimoxazol
less
suggest
fluoroquinolon
monotherapi
proisol
resist
either
clarithromycin
vide
good
clinic
outcom
higher
qualiti
life
azithromycin
full
pneumonia
lower
cost
set
isol
nonsuscept
intermedi
plu
resist
penicillin
vari
geograph
communityacquir
pneumonia
region
rang
south
atlant
new
england
studi
isol
col
idsa
recent
publish
guidelin
lect
primari
care
provid
us
manag
cap
provid
recommendashow
penicillin
nonsuscept
among
tion
choos
antimicrobi
therapi
recpneumonia
ommend
includ
pathogenspecif
treatment
h
influenza
isol
resist
case
aetiolog
diagnosi
estabclarithromycin
anoth
studi
pneumonilish
empir
treatment
patient
ae
isol
collect
intermedi
aetiolog
diagnosi
known
whenev
resist
rate
penicillin
aetiolog
organ
determin
chang
macrolid
cotrimoxazol
antimicrobi
agent
cost
effect
least
tetracyclin
toxic
narrow
spectrum
encopd
patient
aecb
highrisk
faccourag
recommend
treat
patient
tor
usual
treat
outpati
basi
requir
empir
antibacteri
select
set
sputum
gramstain
cultur
seem
base
like
pathogen
local
resist
patto
cost
effect
recommend
tern
comorbid
condit
sever
ill
opinion
amoxicillinclavulan
acid
newer
site
care
recommend
macrolid
clarithromycin
azithromycin
decis
hospitalis
patient
base
use
firstlin
therapi
fluoroquion
assess
preexist
condit
may
nolon
reserv
secondlin
agent
data
showcompromis
safeti
patient
sent
ing
recent
vitro
trend
macrolid
resist
home
port
pneumonia
outcom
research
among
pneumonia
clinic
failur
team
sever
index
psi
score
greater
class
agent
concern
howev
iii
clinic
judgment
although
concontroversi
relev
vitro
data
cern
misus
overus
fluoroquinolon
clinic
outcom
lack
superior
could
lead
increas
pneumococc
resist
outcom
fluoroquinolon
compar
clinic
failur
use
fluoroquith
newer
macrolid
comnolon
alon
recommend
sever
inbin
clinic
studi
see
tabl
vi
ix
stanc
tabl
xi
suggest
latter
agent
still
use
suc
american
thorac
societi
at
guidecess
line
manag
cap
also
includ
highrisk
patient
aecb
usual
treat
recommend
choos
antimicrobi
therin
hospit
set
patient
sputum
api
tabl
xi
idsa
guidelin
gramstain
cultur
cost
effect
at
recommend
base
patient
stratifithey
help
direct
antibacteri
therapi
cation
accord
site
care
outpati
inpati
patient
often
risk
infect
ward
intens
care
unit
icu
presenc
antibacterialresist
enter
gramneg
cardiopulmonari
diseas
presenc
modibacteria
p
aeruginosa
empir
therapi
may
fy
factor
modifi
factor
defin
clinic
setb
start
intraven
thirdor
fourthgenert
place
patient
risk
infect
at
recommend
outpati
previous
healthi
recent
antibacteri
therapi
macrolid
doxycyclin
cardiopulmonari
diseas
previous
healthi
antibacteri
therapi
within
last
month
respiratori
modifi
factor
f
advanc
macrolid
c
fluoroquinolon
b
alon
advanc
macrolid
c
highdos
amoxicillin
tid
doxycyclin
advanc
macrolid
plu
highdos
amoxicillinclavulan
acid
bid
cardiopulmonari
diseas
andor
modifi
comorbid
recent
antibacteri
therapi
advanc
macrolid
factor
f
g
advanc
respiratori
fluoroquinolon
macrolid
doxycyclineor
respiratori
comorbid
recent
antibacteri
therapi
respiratori
fluoroquinolon
alon
fluoroquinolon
alon
advanc
macrolid
e
suspect
aspir
infect
amoxicillinclavulan
acid
clindamycin
influenza
bacteri
superinfect
e
respiratori
fluoroquinolon
recent
antibacteri
therapi
respiratori
fluoroquinolon
alon
advanc
cardiopulmonari
diseas
andor
modifi
macrolid
plu
h
factor
iv
po
iv
recent
antibacteri
therapi
advanc
macrolid
h
respiratori
advanc
macrolid
c
doxycyclineor
fluoroquinolon
alon
regimen
select
depend
natur
recent
antibacteri
iv
respiratori
fluoroquinolonealon
therapi
cardiopulmonari
diseas
modifi
factor
iv
advanc
macrolid
c
alon
iv
po
iv
advanc
macrolid
c
doxycyclineor
iv
respiratori
fluoroquinolon
alon
pseudomon
infect
unlik
h
either
advanc
macrolid
risk
factor
pseudomon
infect
respiratori
fluoroquinolon
iv
iv
advanc
macrolid
c
pseudomon
infect
unlik
patient
allergi
respiratori
iv
respiratori
fluoroquinolon
fluoroquinolon
without
clindamycin
risk
factor
pseudomon
infect
pseudomon
infect
like
j
either
antipseudomon
agent
k
ciprofloxacin
either
antipseudomon
agent
k
ii
antipseudomon
agent
aminoglycosid
respiratori
fluoroquinolon
ciprofloxacin
ii
antipseudomon
macrolid
agent
aminoglycosid
respiratori
pseudomon
infect
like
patient
allergi
either
fluoroquinolon
macrolid
aztreonam
levofloxacin
ii
aztreonam
moxifloxacin
gatifloxacin
without
aminoglycosid
receiv
treatment
nurs
home
respiratori
fluoroquinolon
alon
particular
recommend
amoxicillinclavulan
acid
advanc
macrolid
hospitalis
medic
ward
icu
erythromycin
azithromycin
clarithromycin
b
moxifloxacin
gatifloxacin
levofloxacin
gemifloxacin
gemifloxacin
avail
oral
c
azithromycin
clarithromycin
chronic
obstruct
pulmonari
diseas
diabet
mellitu
renal
congest
heart
failur
malign
e
highdos
amoxicillin
highdos
amoxicillinclavulan
acid
cefpodoxim
cefprozil
cefuroxim
f
see
text
section
g
select
oral
antibacteri
includ
oral
cefpodoxim
cefuroxim
highdos
amoxicillin
amoxicillinclavulan
acid
h
cefotaxim
ceftriaxon
ampicillinsulbactam
ertapenem
ertapenem
recent
approv
use
oncedaili
parenter
treatment
littl
experi
thu
far
select
iv
antibacteri
includ
cefotaxim
ceftriaxon
ampicillinsulbactam
atsdefin
risk
factor
infect
pseudomona
aeruginosa
includ
follow
structur
lung
diseas
bronchiectasi
antibacteri
day
past
month
corticosteroid
therapi
mgday
prednison
malnutrit
j
risk
factor
pseudomon
infect
includ
sever
structur
lung
diseas
eg
bronchiectasi
recent
antibacteri
therapi
stay
hospit
especi
icu
k
piperacillin
piperacillintazobactam
imipenem
meropenem
cefepim
bid
twice
daili
icu
intens
care
unit
iv
intraven
po
oral
tid
three
time
daili
drug
resist
pneumonia
enter
gramneg
fifth
day
hospitalis
later
asbacteria
p
aeruginosa
risk
factor
infect
sume
result
organ
acquir
drugresist
pneumonia
includ
age
hospit
treat
accordingli
year
therapi
past
month
alcoempir
earli
adequ
antibacteri
therhol
immunosuppress
ill
includ
cortiapi
base
knowledg
like
costeroid
therapi
hiv
infect
multipl
infect
organ
shown
reduc
mormed
comorbid
exposur
child
biditi
mortal
hap
at
dedaycar
centr
risk
factor
infect
enterfin
pathogen
like
aetiolog
ic
gramneg
bacteria
includ
resid
hap
absenc
specif
risk
factor
see
nurs
home
underli
cardiopulmonari
diseas
bacteria
includ
e
coli
enterobact
multipl
medic
comorbid
recent
anspp
klebsiella
spp
proteu
spp
serratia
marcestibacteri
therapi
risk
factor
infect
p
cen
h
influenza
methicillinsensit
aureu
aeruginosa
includ
structur
lung
diseas
bronchiand
pneumonia
risk
factor
addit
ectasi
antibacteri
therapi
day
pathogen
includ
wit
aspir
recent
abin
past
month
corticosteroid
therapi
domin
surgeri
coma
head
trauma
recent
influenequival
mgday
prednison
malnuza
histori
intraven
drug
use
diabet
renal
trition
recommend
antibacteri
regimen
failur
highdos
corticosteroid
prolong
icu
given
tabl
xi
idsa
guidelin
stay
structur
lung
diseas
antibacteri
use
fluoroquinolon
often
recommend
singl
onset
pneumonia
prolong
mechan
agent
ventil
presenc
risk
factor
inoth
organis
made
recommend
creas
probabl
infect
due
treatment
cap
cdc
focus
primap
aeruginosa
acinetobact
spp
mrsa
anaerrili
drugresist
pneumonia
defin
obe
legionella
spp
mic
recommend
oral
plu
initi
empir
therapi
hap
vena
macrolid
tetracyclin
even
pneumococc
tilatorassoci
pneumonia
patient
resist
concern
intraven
known
risk
factor
multidrugresist
pathogen
plu
macrolid
recommend
empir
earli
onset
at
recommend
monothertherapi
hospitalis
patient
cap
cdc
api
ceftriaxon
ampicillinsulbactam
emphasis
fluoroquinolon
ertapenem
quinolon
ciprofloxacin
levofloxus
routin
treat
cap
reserv
acin
moxifloxacin
patient
late
onset
patient
fail
regimen
diseas
risk
factor
multidrugresist
bactewho
document
highlevel
drugresist
ria
at
recommend
patient
treat
pneumonia
contrast
american
recomwith
antipseudomon
cephalosporin
cefepim
mendat
canadian
guidelin
call
reor
ceftazidim
antipseudomon
carbapenem
spiratori
fluoroquinolon
first
choic
imipenemcilastin
meropenem
admit
hospit
lactamas
inhibitor
combin
piperacillin
tazobactam
plu
antipseudomon
hospitalacquir
pneumonia
nolon
ciprofloxacin
levofloxacin
aminoglycosid
linezolid
vancomycin
at
guidelin
manag
hap
use
mrsa
suspect
base
time
onset
hospitalis
studi
use
fluoroquinolon
hap
diseas
sever
presenc
risk
factor
mainli
involv
use
ciprofloxacin
one
specif
organ
recommend
hap
studi
show
equival
highdos
levofloxacin
begin
third
fourth
day
hospitalisawith
imipenemcilastatin
follow
oral
ciprofloxt
treat
cap
see
section
contrast
acin
tabl
vi
use
newer
fluoroit
recommend
hap
encount
quinolon
gatifloxacin
moxifloxacin
increas
preval
levofloxacin
resist
evalu
set
among
pneumococc
isol
collect
across
ciprofloxacin
remain
activ
quinolon
us
figur
exceed
certain
state
p
aeruginosa
vitro
levofloxacin
may
massachusett
colorado
worria
effect
clinic
set
given
superior
greater
concern
crossresist
pharmacokinet
despit
activ
among
fluoroquinolon
clearli
p
aeruginosa
howev
use
fluoroquinolon
shown
occur
pathogen
expos
monotherapi
hap
justifi
sinc
high
older
less
potent
agent
select
singlestep
lowclin
failur
rate
evolut
resist
level
resist
mutant
mutant
may
p
aeruginosa
observ
ciprofloxdecreas
suscept
newer
fluoroquinolon
acin
monotherapi
fluoroquinolon
may
may
acquir
highlevel
resist
additionus
altern
aminoglycosid
comal
mutat
second
target
gene
binat
antipseudomon
investig
suggest
less
potent
concern
renal
dysfunct
fluoroquinolon
ciprofloxacin
levofloxacin
drug
reliabl
synergist
abandon
favour
potent
one
gaagainst
p
aeruginosa
aminoglycotifloxacin
moxifloxacin
gemifloxacin
side
treatment
cap
effort
prevent
class
resist
clinic
failur
conclus
document
ciprofloxacin
lead
us
fda
suggest
drug
use
lower
respirnew
fluoroquinolon
levofloxacin
atori
tract
infect
caus
pneumonia
moxifloxacin
gatifloxacin
gemifloxacin
interest
similar
number
levofloxacin
sever
attribut
make
good
choic
failur
also
report
recomth
therapi
lower
respiratori
tract
infect
mendat
forthcom
theoret
excel
intrins
activ
ciprofloxacin
would
expect
less
effica
pneumonia
h
influenza
catarrhali
ciou
infect
caus
pneumonia
beth
atyp
respiratori
pathogen
caus
pharmacodynam
ratio
pharmacokinet
allow
singl
daili
dose
adminisnew
agent
tabl
v
pharmacodynam
ratrat
gener
well
toler
tio
levofloxacin
gatifloxacin
good
safeti
profil
clinic
trial
moxifloxacin
gemifloxacin
whether
shown
achiev
high
microbiolog
eradiwil
make
differ
patient
outcom
remain
cation
clinic
success
rate
compar
seen
data
publish
recent
clinic
trial
favour
newer
involv
levofloxacin
gatifloxacin
moxifloxacin
macrolid
unfortun
bacteria
becom
reand
gemifloxacin
suggest
littl
differsist
agent
seri
simpl
enc
among
fluoroquinolon
eradicaspontan
mutat
numer
studi
rang
tion
rate
pneumonia
tabl
vi
ix
vitro
experi
case
report
larg
approach
origin
recommend
consurveil
databas
shown
resist
servat
efficaci
pneumonican
occur
current
overal
prevaa
also
seem
appropri
fluoroquinolon
lenc
resist
newer
fluoroquinolon
approach
entail
reduct
prescrib
low
necessarili
reassur
austin
drug
whose
consumpt
correl
strongli
et
al
point
typic
long
period
resist
ii
develop
new
formul
lowlevel
resist
preced
rapid
inadministr
strategi
deal
resist
creas
resist
case
strain
iii
use
antibacteri
maximrsa
vancomycinresist
enterococci
penim
capac
bacteri
erad
cillinresist
pneumonia
recent
report
opinion
ciprofloxacin
use
lower
acknowledg
respiratori
tract
infect
concern
newli
dr
sham
conflict
interest
directli
releas
cipro
xr
formul
consist
relev
content
manuscript
dr
evan
receiv
fund
basic
research
quinolon
orthobilay
matrix
first
layer
releas
ciprofloxacin
